What was the outcome of the APLASA study?
The APLASA study was a double-blind, placebo-controlled trial for the primary prevention of thrombosis in asymptomatic patients who were persistently aPL positive that compared low-dose aspirin (81 mg/d; n=48) with placebo (n=50) over an average follow-up of 2.30 0.95 years. The rates of acute thrombosis were 2.75 per 100 patient-years for the aspirin-treated subjects and 0 per 100 patient-years for placebo, however, the sample size was relatively small; thus, the study was insufficiently powered.